LOGIN
ID
PW
MemberShip
2024-10-22 10:17
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Ipsen Korea appoints Yang mi-sun as new CEO
by
Eo, Yun-Ho
Sep 20, 2024 05:51am
Ipsen Korea has appointed Yang Mi-sun, AstraZeneca Korea¡¯s former Business Unit Director, as the new Chief Executive Officer (CEO). Sources said that Ipsen Korea has appointed its new CEO, replacing former CEO Audrey Schweitzer after the end of her term. Audrey Schweitzer has been in charge of Ipsen Korea since 2021. Yang is an indust
Company
Inventage Lab to codevelop a long-acting injectable with BI
by
Lee, Seok-Jun
Sep 20, 2024 05:51am
Inventage Lab (CEO Ju-Hee Kim) announced on the 19th that it has signed an agreement with Boehringer Ingelheim, a German multinational pharmaceutical company, to co-develop a long-acting injectable formulation for a new peptide drug. Inventage Lab will develop a long-acting injectable formulation based on Boehringer Ingelheim's drug cand
Company
Samsung Bioepis recruits Lina Choi as new global head
by
Nho, Byung Chul
Sep 19, 2024 05:48am
Samsung Bioepis garners attention as the company recruits specialists to strengthen its global entry capacity. Sources said that Samsung Bioepis has recruited Linda Choi, Vice President, as the Head of Global Commercial in August. Choi studied pharmacy at Ohio State University College of Pharmacy and has 28 years of experience in mult
Company
Will Columvi be reviewed for reimb by CDDC in OCT?
by
Eo, Yun-Ho
Sep 19, 2024 05:48am
Demand is rising for the reimbursement of ¡®Columvi,¡¯ the first bispecific antibody treatment option for lymphoma, in Korea. The Korea Leukemia Patients Organization has requested the CD20-CD3 bispecific antibody for diffuse large B-cell lymphoma (DLBCL) Columvi (glofitamab) be redeliberated at the Health Insurance Review and Assessment
Company
Reimb for orphan drug 'Welireg' for cancer has been denied
by
Eo, Yun-Ho
Sep 19, 2024 05:48am
An orphan drug, 'Welireg,' for cancer still faces challenges in entering insurance reimbursement coverage. Sources said that MSD Korea is preparing to reapply for reimbursement review of its oral hypoxia-inducible factor 2 alpha (HIF-2¥á) inhibitor, Welireg (belzutifan), after failing to pass the Cancer Disease Review Committee (CDRC) rev
Company
JAK inhibitor 'Jyseleca' approved for use at 'Big 5'
by
Eo, Yun-Ho
Sep 13, 2024 05:50am
The JAK inhibitor 'Jyseleca' has been successfully introduced to general hospitals. Sources said Jyseleca, the fifth JAK inhibitor in South Korea, has passed the drug committees (DC) of 'Big 5' tertiary hospitals, including Samsung Medical Center, Seoul University Hospital, Seoul St. Mary's Hospital, Seoul Asan Medical Center, and Sincho
Company
Global guidelines recommend Leclaza combination therapy
by
Son, Hyung-Min
Sep 13, 2024 05:49am
Leclaza plus Rybrevant combination therapy has been listed as a first-line therapy in global guidelines after demonstrating improvements in survival rates. Leclaza plus Rybrevant combination therapy, which is the new treatment for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), received U.S. Food and Drug A
Company
Hugel offers guide to safe injection of dermal fillers
by
¾îÀ±È£
Sep 12, 2024 04:16pm
Hugel Inc., a leading global medical aesthetics company, said on Thursday it hosted The Chaeum Safe-tech Session (TSS) seminar for injection of dermal fillers for some 20 medical experts in Seoul on September 11 to improve their understanding of safe treatment and Hugel¡¯s hyaluronic acid filler brand The Chaeum. The lecture covered anatom
Company
Yuhan earns ₩80B milestone with Leclaza's FDA nod
by
Chon, Seung-Hyun
Sep 12, 2024 05:51am
On the 11th, Yuhan Corp announced that it will receive USD 60 million (approximately KRW 80 billion) as milestone payments from Janssen Biotech for Leclaza. The company explained, ¡°This is a milestone payment (step-by-step technical fee) for the commercialization of Leclaza and Janssen Biotech's amivantamab combination therapy.¡± The
Company
HK inno.N signs supply deal with Pfizer for COVID-19 vaccine
by
Son, Hyung-Min
Sep 12, 2024 05:51am
HK inno.N announced on September 11th that it has signed an agreement with Pfizer Korea for the domestic distribution of the new COVID-19 vaccine. On September 10th, two companies held an agreement ceremony celebrating the strategic collaboration for the distribution of Pfizer Korea's COVID-19 vaccine, 'Comirnaty JN.1 Inj (bretovameran),
1
2
3
4
5
6
7
8
9
10
>